|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||9.50 - 9.50|
|52-week range||6.92 - 13.65|
|Beta (5Y monthly)||1.47|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Nov 2017|
|1y target est||N/A|
TEL AVIV, Israel, July 28, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) released a new report highlighting the billions of dollars saved by the healthcare system due to its generic medicines, and the Company’s contribution to economies in 2020.
TEL AVIV, Israel, July 28, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2021.
TEL AVIV, Israel & PARSIPPANY, N.J., July 21, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Brendan O’Grady, Executive Vice President, North America Commercial, will leave Teva to pursue a career opportunity outside of the pharmaceutical industry, and Sven Dethlefs, who currently serves as Teva’s Executive Vice President, Global Marketing and Portfolio and International Markets Commercial has been appointed the new head of North A